Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | EV-302: complete response outcomes of EV and pembrolizumab in la/mUC

Jacqueline Brown • 2 Jun 2025
ASCO 2025
Genitourinary Cancer Urothelial Carcinoma Antibodies Checkpoint Inhibitors Enfortumab vedotin Pembrolizumab
EV-302

Jacqueline Brown, MD, Emory University School of Medicine, Atlanta, GA, comments on an exploratory analysis from the Phase III EV-302/KEYNOTE-A39 trial (NCT04223856) of enfortumab vedotin (EV) plus pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. The combination more than doubled complete response rates compared to chemotherapy and was associated with prolonged progression-free survival. Safety among responders was manageable and consistent with known profiles. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jacqueline Brown

What are the best second-line treatment options in urothelial carcinoma?
0:54
What are the best second-line treatment options in urothelial carcinoma?
Jacqueline Brown • 2 Jun 2025
Evaluating the significance of ctDNA status in the NIAGARA trial
0:53
Evaluating the significance of ctDNA status in the NIAGARA trial
Jacqueline Brown • 2 Jun 2025
Final results of the CheckMate 901 trial in cisplatin-ineligible patients with mUC
1:21
Final results of the CheckMate 901 trial in cisplatin-ineligible patients with mUC
Jacqueline Brown • 2 Jun 2025
JAVELIN Bladder Medley: avelumab & sacituzumab govitecan in urothelial carcinoma
1:07
JAVELIN Bladder Medley: avelumab & sacituzumab govitecan in urothelial carcinoma
Jacqueline Brown • 2 Jun 2025

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals